TRex Bio (NASDAQ: TRXB) recently received a number of ratings updates from brokerages and research firms:
- 11/3/2026 – TRex Bio is now covered by Zacks Research. They set a “hold” rating on the stock.
- 11/3/2026 – TRex Bio is now covered by Evercore. They set a “strong-buy” rating on the stock.
- 11/3/2026 – TRex Bio is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
- 11/3/2026 – TRex Bio is now covered by Stifel Nicolaus. They set a “buy” rating and a $39.00 price target on the stock.
- 11/3/2026 – TRex Bio is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $20.00 price target on the stock.
- 11/2/2026 – TRex Bio is now covered by Wedbush. They set an “outperform” rating and a $30.00 price target on the stock.
TRex Bio Stock Down 0.5%
Shares of NASDAQ TRXB traded down $0.05 during midday trading on Thursday, reaching $9.34. 116,414 shares of the stock were exchanged, compared to its average volume of 118,640. TRex Bio, Inc. has a twelve month low of $9.06 and a twelve month high of $16.56.
TRex Bio (NASDAQ:TRXB – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($10.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($9.37). Equities analysts predict that TRex Bio, Inc. will post -5.84 EPS for the current fiscal year.
Insider Buying and Selling at TRex Bio
In other news, major shareholder Alexandria Venture Investments bought 178,571 shares of the firm’s stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the transaction, the insider directly owned 1,346,501 shares in the company, valued at $18,851,014. The trade was a 15.29% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
TRexBio is a biotechnology company developing therapies for autoimmune and inflammatory diseases. Its research focuses on regulatory T cells, which help control immune responses in tissues. The company uses its research platform to identify tissue-specific regulatory T-cell populations and explore ways to target them therapeutically. Its work is aimed at developing treatments based on the role these cells play in particular diseases and tissues. Founded in 2018, TRexBio is based in South San Francisco, California.
Featured Stories
- Five stocks we like better than TRex Bio
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
Receive News & Ratings for TRex Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.
